[go: up one dir, main page]

WO1997031611A3 - Apport d'agents therapeutiques a la prostate - Google Patents

Apport d'agents therapeutiques a la prostate Download PDF

Info

Publication number
WO1997031611A3
WO1997031611A3 PCT/US1997/003228 US9703228W WO9731611A3 WO 1997031611 A3 WO1997031611 A3 WO 1997031611A3 US 9703228 W US9703228 W US 9703228W WO 9731611 A3 WO9731611 A3 WO 9731611A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
prostatic hyperplasia
methods
delivery
apoptotic
Prior art date
Application number
PCT/US1997/003228
Other languages
English (en)
Other versions
WO1997031611A2 (fr
Inventor
David T Hung
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to EP97914829A priority Critical patent/EP0886524A2/fr
Priority to AU21937/97A priority patent/AU2193797A/en
Publication of WO1997031611A2 publication Critical patent/WO1997031611A2/fr
Publication of WO1997031611A3 publication Critical patent/WO1997031611A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

Cette invention se rapporte à de nouveaux procédés servant à acheminer des agents proapoptotiques et/ou antiprolifératifs à la glande de la prostate, en vue de traiter les troubles de la prostate. Des kits de réalisation de ces procédés sont également présentés. Les procédés et les kits objets de cette invention peuvent utiliser un système d'apport par cathéter faisant usage de la phorésie et/ou de la pression pour contribuer à l'acheminement de ces agents proapoptotiques et/ou antiprolifératifs à la glande de la prostate et/ou dans les régions qui entourent cette glande.
PCT/US1997/003228 1996-03-01 1997-02-28 Apport d'agents therapeutiques a la prostate WO1997031611A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP97914829A EP0886524A2 (fr) 1996-03-01 1997-02-28 Apport d'agents therapeutiques a la prostate
AU21937/97A AU2193797A (en) 1996-03-01 1997-02-28 Delivery of therapeutic agents to the prostate

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US1267296P 1996-03-01 1996-03-01
US60/012,672 1996-03-01
US1281796P 1996-03-05 1996-03-05
US60/012,817 1996-03-05
US2153996P 1996-07-11 1996-07-11
US60/021,539 1996-07-11
US80718197A 1997-02-27 1997-02-27
US08/807,181 1997-02-27

Publications (2)

Publication Number Publication Date
WO1997031611A2 WO1997031611A2 (fr) 1997-09-04
WO1997031611A3 true WO1997031611A3 (fr) 1997-11-13

Family

ID=27486210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/003228 WO1997031611A2 (fr) 1996-03-01 1997-02-28 Apport d'agents therapeutiques a la prostate

Country Status (3)

Country Link
EP (1) EP0886524A2 (fr)
AU (1) AU2193797A (fr)
WO (1) WO1997031611A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794545B1 (en) 1999-04-30 2004-09-21 Slil Biomedical Corporation Conformationally restricted polyamine analogs as disease therapies
US7279502B2 (en) 1999-04-30 2007-10-09 Cellgate, Inc. Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US7312244B2 (en) 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents
US7453011B2 (en) 2001-12-07 2008-11-18 Progen Pharmaceuticals, Inc. Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3454799A (en) * 1998-03-30 1999-10-18 Baylor College Of Medicine Regulated apoptosis using chemically induced dimerization of apoptosis factors
DE60021381T2 (de) * 1999-04-30 2006-05-24 Slil Biomedical Corp., Madison Chinonverbindungen zur behandlung von krankheiten
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
WO2001021217A2 (fr) * 1999-09-23 2001-03-29 Genvec, Inc. Procede de traitement prophylactique ou therapeutique des cellules de la prostate
US6939896B2 (en) * 1999-12-21 2005-09-06 Astrazeneca Ab Cd45 inhibitors
US7837670B2 (en) 2005-03-22 2010-11-23 Boston Scientific Scimed, Inc. Methods and devices for delivering therapeutic agents into the prostate gland

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007897A (en) * 1989-05-30 1991-04-16 Kalb Irvin M Drug delivery catheter
WO1994006910A1 (fr) * 1992-09-18 1994-03-31 Canji, Inc. Therapie genique au moyen d'un vecteur retroviral a gene de suppression tumorale
EP0639573A1 (fr) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
WO1995023141A1 (fr) * 1994-02-23 1995-08-31 Pfizer Inc. Derives de la quinazoline a substitution 4-heterocyclyle, procedes d'elaboration et utilisations correspondantes comme agents anticancereux
EP0688766A1 (fr) * 1994-06-20 1995-12-27 Hoechst Aktiengesellschaft Guanidines d'acides alcénylcarboxyliques substituées par un groupe phényle portant des groupes perfluoroalcoyle, procédé pour leur préparation, leur utilisation comme médicament ou agent diagnostique, ainsi que médicament les contenant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007897A (en) * 1989-05-30 1991-04-16 Kalb Irvin M Drug delivery catheter
WO1994006910A1 (fr) * 1992-09-18 1994-03-31 Canji, Inc. Therapie genique au moyen d'un vecteur retroviral a gene de suppression tumorale
EP0639573A1 (fr) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
WO1995023141A1 (fr) * 1994-02-23 1995-08-31 Pfizer Inc. Derives de la quinazoline a substitution 4-heterocyclyle, procedes d'elaboration et utilisations correspondantes comme agents anticancereux
EP0688766A1 (fr) * 1994-06-20 1995-12-27 Hoechst Aktiengesellschaft Guanidines d'acides alcénylcarboxyliques substituées par un groupe phényle portant des groupes perfluoroalcoyle, procédé pour leur préparation, leur utilisation comme médicament ou agent diagnostique, ainsi que médicament les contenant

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 123, no. 25, 1995, Columbus, Ohio, US; abstract no. 332818, MIURA, M. ET AL: "Molecular mecanisms and signalling pathway of apoptosis" page 428; column 2; XP002034678 *
COHEN J.J.: "Apoptosis", IMMUNOLOGY TODAY, vol. 14, no. 3, 1993, pages 126 - 130, XP002034675 *
COHEN J.J.: "Exponential growth in apoptosis", IMMUNOLOGY TODAY, vol. 16, no. 7, 1995, pages 346 - 348, XP002034676 *
COLOMBEL M.: "Growth factors, cell proliferation and apoptosis in prostate adenoma", BIOMEDICINE & PHARMACOTHERAPY, vol. 48, no. 1 suppl, 1994, pages 25s - 26s, XP002034673 *
EASTHAM, J.A. ET AL: "In vivo gene therapy with p53 or p21 adenovirus for prostate cancer", CANCER RESEARCH, vol. 55, 1995, pages 5151 - 5155, XP002034677 *
Jikken Igaku, 1995, 13(16), 1824-7 (Japan) *
RITTMASTER R.S. ET AL: "Evidence for atrophy and apoptosis in the prostates of men given Finasteride", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 81, no. 2, February 1996 (1996-02-01), pages 814 - 819, XP002034672 *
SILVER, R.I. ET AL: "Androgen suppression therapy for benign prostatic hyperplasia", CURRENT OPINION IN UROLOGY, vol. 4, no. 1, 1994, pages 22 - 28, XP002034674 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794545B1 (en) 1999-04-30 2004-09-21 Slil Biomedical Corporation Conformationally restricted polyamine analogs as disease therapies
US7279502B2 (en) 1999-04-30 2007-10-09 Cellgate, Inc. Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US7312244B2 (en) 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents
US7453011B2 (en) 2001-12-07 2008-11-18 Progen Pharmaceuticals, Inc. Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor

Also Published As

Publication number Publication date
EP0886524A2 (fr) 1998-12-30
AU2193797A (en) 1997-09-16
WO1997031611A2 (fr) 1997-09-04

Similar Documents

Publication Publication Date Title
WO1997044063A3 (fr) Conjugues d'acide cis-docosahexanoïque et d'agents pharmaceutiques
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
ATE185971T1 (de) Kombinationspräparat zur behandlung hypogonadaler männer sowie männern mit hypophysenerkrankungen
CA2195093A1 (fr) Utilisation du droloxifene pour le traitement des affections prostatiques, de l'endometriose et de l'obesite
ZA972929B (en) Systems for the treatment of commingled wastes and methods for treating commingled wastes.
CA2177209A1 (fr) Dispositif de mobilisation de l'articulation sacro-iliaque
TR200001117T2 (tr) Mukozal dokudaki enflomasyonu önlemek ve tedavi etmek için maddeler ve yöntemler.
WO2000038730A3 (fr) Techniques permettant d'utiliser un inhibiteur de cyclooxygenase-2 et un ou plusieurs agents antineoplasiques comme therapie combinee pour traiter les maladies neoplasiques
DE69739017D1 (de) Kartenartiges Registriermittel, Beglaubigungsverfahren und -vorrichtung für das Registriermittel, System zum Erzeugen eines solchen Registriermittels, Chiffriersystem und Dekodierer dazu, und Registriermittel
CA2255891A1 (fr) Compositions et methodes pour traiter ou prevenir des maladies des voies corporelles
DE59611481D1 (en) Chromatin-regulatorgene
PL328858A1 (en) Immunogenous peptides
BR9703302A (pt) Aparelho e método para a geração e uso de ìons férricos
IT1306553B1 (it) Procedimento e dispositivo per la determinazione dell'interasse deiveicoli sterzanti.
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
WO1997031611A3 (fr) Apport d'agents therapeutiques a la prostate
IL129356A0 (en) Conjugates useful in the treatment of prostate cancer
WO1994008578A3 (fr) Activite tumoricide des ansamycines benzoquinonoides contre le cancer de la prostate et les malignites neurales primitives
EP2348031A3 (fr) Modification structurale de 17-alpha-substitué-11-bêta-substitué-4-aryle et 21-substitué 19-norpregnadienedione en tant que nouveaux agents antiprogestatifs
DK1071433T3 (da) 2',2'-difluornucleosider til immunosuppressiv behandling og kombinationspræparater
WO2000013703A3 (fr) Methodes de traitement de l'hypertension et compositions utiles a cet effet
WO1998022101A3 (fr) Procede d'utilisation d'inhibiteurs de cyclo-oxygenase-2 comme agents anti-angiogeniques
CA2275167A1 (fr) Utilisation locale d'agonistes opioides kappa dans le traitement de la douleur oculaire
ZA976852B (en) Stable dispersions of metal passivation agents and methods for making them.
AU1278600A (en) Novel therapeutic application of nicergoline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1997914829

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97531182

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997914829

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1997914829

Country of ref document: EP